In MS, the immune system damages the insulating coating on nerve cells known as myelin. The human body […]
The first ever treatment for secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, has been approved in Australia.
The Federal Government has expanded the PBS listing of fingolimod (Gilenya) and natalizumab (Tysabri) to include younger people. […]